Illustrative image.
Yescarta
Axicabtagene Ciloleucel
$666700.00
1 bag
BrandBranded medicine· By Kite Pharma
Choose a pack
- Selected pack
Packs in this delivery
Test mode: no payment is taken. View cart
Ships cold, in insulated packing
This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
FDA boxed warningCytokine release syndrome, neurologic toxicities and secondary hematological malignancies
Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving YESCARTA. Do not administer YESCARTA to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.
Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving YESCARTA, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with YESCARTA. Provide supportive care and/or corticosteroids as needed.
T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including YESCARTA.
About Yescarta
Overview
Yescarta (axicabtagene ciloleucel) is an immunotherapy made from a patient’s own genetically modified T cells and supplied in a patient-specific infusion bag. It treats adults with large B-cell lymphoma that has not responded to initial chemoimmunotherapy or has returned within 12 months of that treatment, or that has returned or not responded after at least two lines of systemic treatment. It also treats adults with follicular lymphoma that has returned or not responded after at least two lines of systemic treatment; this use has accelerated approval based on response rates, and continued approval may depend on confirmatory trials verifying clinical benefit. The modified T cells recognise and kill cells carrying a protein called CD19, including cancer cells and normal B cells.
What it treats
- Large B-cell lymphoma in adults that does not respond to initial chemoimmunotherapy or returns within 12 months of that treatment. - Large B-cell lymphoma in adults that returns or does not respond after at least two lines of systemic treatment, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. - Follicular lymphoma in adults that returns or does not respond after at least two lines of systemic treatment. This use has accelerated approval based on response rate; continued approval may depend on confirmatory trials verifying clinical benefit.
Safety information
Side effects
Common side effects include cytokine release syndrome (CRS), fever, low blood pressure, changes in brain function, tiredness, a fast heartbeat, headache, nausea, fever with low neutrophil counts, diarrhoea, muscle and joint pain, infections, chills and reduced appetite. Contact a doctor promptly for CRS, changes in brain function, fever with low neutrophil counts, serious infections or allergic reactions during infusion. Severe reductions in white blood cells, red blood cells and platelets can occur; low blood cell counts may last for several weeks after treatment and require blood count monitoring. Severely low blood phosphate levels can also occur. Low antibody levels may require monitoring and replacement treatment. Secondary cancers, including T-cell cancers, have occurred after treatment with Yescarta. Contact your doctor if a new cancer is diagnosed after treatment.
FDA boxed warning
Cytokine release syndrome, neurologic toxicities and secondary hematological malignancies
Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving YESCARTA. Do not administer YESCARTA to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.
Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving YESCARTA, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with YESCARTA. Provide supportive care and/or corticosteroids as needed.
T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including YESCARTA.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
The FDA label lists no contraindications to Yescarta. However, important risks require monitoring: - Hypersensitivity reactions during infusion. - Serious infections, which require monitoring and appropriate treatment. - Severely low blood cell counts that may last several weeks after infusion. Complete blood counts should be monitored. - Low antibody levels, which require monitoring and replacement therapy. - New cancers, including T-cell cancers, have occurred after treatment with genetically modified T-cell therapies, including Yescarta. If a new cancer develops after treatment, contact Kite at 1-844-454-KITE (5483).
Using Yescarta
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store in the original carton below 25°C, protected from light. Do not freeze. Prepared infusions are handled by the treating clinic. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label YESCARTA (AXICABTAGENE CILOLEUCEL) SUSPENSION [KITE PHARMA, INC.] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Busulfex
Busulfan
By Otsuka America Pharmaceutical
Vial · from 1 per pack
Also for cancer treatment
Brand $551.00
Brukinsa
Zanubrutinib
By BeiGene
Capsules · from 120 per pack
Also for cancer treatment
Brand $10,520.00
Temodar
Temozolomide
By Orion
Tablets · from 5 per pack
Also for cancer treatment
Brand from $46.00
Ojjaara
Momelotinib (momelotinib Dihydrochloride)
By GlaxoSmithKline
Tablets · from 30 per pack
Also for cancer treatment
Brand $12,585.00